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BACkGrounD: The prevalence of cannabis use in HIV-infected 
individuals is high and its long-term effects are unclear. 
MEtHoDS: The prevalence, perceived benefits and consequences, 
and predictors of cannabis use were studied using a cross-sectional 
survey in two immunodeficiency clinics in Maritime Canada. 
rESuLtS: Current cannabis use was identified in 38.5% (87 of 226) of 
participants. Almost all cannabis users (85 of 87 [97.7%]) acknowledged 
its use for recreational purposes, with 21.8% (19 of 87) reporting medic-
inal cannabis use. The majority of patients enrolled in the present study 
reported mild or no symptoms related to HIV (n=179). Overall, 80.5% 
(70 of 87) of the cannabis-using participants reported a symptom-
relieving benefit, mostly for relief of stress, anorexia or pain. Participants 
consumed a mean (± SD) of 18.3±21.1 g of cannabis per month and 
spent an average of $105.15±109.87 on cannabis per month. Cannabis 
use was associated with rural residence, lower income level, driving 
under the influence of a substance, and consumption of ecstasy and 
tobacco. Income level, ecstasy use and tobacco use were retained as sig-
nificant predictors in regression modelling. Cannabis use was not associ-
ated with adverse psychological outcomes. 
DISCuSSIon: Prolonged previous cannabis consumption and the 
substantial overlap between recreational and medicinal cannabis use 
highlight the challenges in obtaining a tenable definition of medicinal 
cannabis therapy.
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Les modes et les corrélats de consommation de 
cannabis chez des personnes atteintes du VIH-sida 
dans les Maritimes, au Canada
HIStorIQuE : La prévalence de consommation de cannabis est 
élevée chez les personnes infectées par le VIH, mais on n’en connaît 
pas les effets à long terme.
MÉtHoDoLoGIE : Les chercheurs ont étudié la prévalence, les 
avantages perçus et les conséquences et prédicteurs de consommation 
de cannabis au moyen d’un sondage transversal mené dans deux cli-
niques d’immunodéficience des Maritimes, au Canada.
rÉSuLtAtS : Les chercheurs ont constaté une consommation cou-
rante de cannabis chez 38,5 % des participants (87 sur 226). Presque 
tous les consommateurs de cannabis (85 sur 87 [97,7 %]) admettaient en 
prendre pour des fins récréatives, et 21,8 % (19 sur 87) indiquaient en 
prendre pour des fins médicinales. La majorité des patients qui partici-
paient à la présente étude a déclaré des symptômes du VIH légers, sinon 
inexistants (n=179). Dans l’ensemble, 80,5 % des participants consom-
mateurs de cannabis (70 sur 87) ont affirmé remarquer un soulagement 
des symptômes, particulièrement le stress, l’anorexie ou la douleur. Les 
participants consommaient en moyenne 18,3±21,1 g de cannabis par 
mois et dépensaient en moyenne 105,15±109,87 $ par mois pour se le 
procurer. La consommation de cannabis était liée à un logement en 
milieu rural, à un niveau de revenu plus bas, à la conduite sous 
l’influence d’une substance et à la consommation d’ecstasy et de tabac. 
Le niveau de revenu, la consommation d’ecstasy et la consommation de 
tabac étaient considérés comme des prédicteurs importants selon le 
modèle de régression. La consommation de cannabis ne s’associait pas à 
des résultats psychologiques indésirables.
EXPoSÉ : Une consommation antérieure prolongée de cannabis et le 
chevauchement important entre la consommation de cannabis à des 
fins récréatives et médicinales font ressortir la difficulté d’obtenir une 
définition viable du traitement médicinal par le cannabis.
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Preparations of the plant Cannabis sativa (ie, cannabis or marijuana) have been used for both psychoactive and therapeutic purposes for 
millennia (1). Despite the fact that it was made illegal by most coun-
tries early in the 20th century, cannabis is the most commonly used 
illicit drug globally (2). Canada had the highest prevalence of canna-
bis use in the industrialized world in 2004, with 16.8% of Canadians 
between 15 and 64 years of age having smoked cannabis or its deriva-
tives in the previous year (3). The 2004 Canadian Addiction survey 
indicated that most cannabis use was recreational, with 14.1% of 
respondents >15 years of age having used cannabis in the previous 
year, of whom 18.1% reported daily use (4). Twenty-eight percent of 
respondents reported using cannabis to alleviate a medical condition, 
although this was not the principal reason for its reported use. 
The major active ingredient in cannabis is ∆-9-tetrahydro-
cannibinol. More than 80 other phytocannabinoids have been 
identified in C sativa in addition to ∆-9-tetrahydrocannibinol 
(5). Synthetic cannabinoids refer to those that have been man-
made. Three prescribed cannabinoids can be obtained in Canada: 
a synthetic ∆-9-tetrahydrocannabinol (dronabinol), marketed as 
Marinol (Unimed Pharmaceuticals, USA) for HIV-associated anor-
exia and chemotherapy-induced nausea and vomiting; a synthetic 
∆-9-tetrahydrocannabinol (nabilone), marketed as Cesamet (Valeant 
Canada LP, Canada) for chemotherapy-induced nausea and vomit-
ing; and a herbal extract oromucosal spray, marketed as Sativex (GW 
Pharmaceuticals, United Kingdom) for neuropathic pain in multiple 
sclerosis. 
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Access to nonprescription herbal cannabis was authorized for med-
ical purposes in Canada through the Marijuana Medical Access 
Regulations in 2001 (6). There were approximately 5000 medicinal 
cannabis users registered through Health Canada in 2010 (7). Despite 
the existence of four potential sources of medicinal cannabis, the 
majority of medicinal cannabis users living with HIV/AIDS in Canada 
use smoked herbal cannabis obtained from illegal sources (8,9). This 
raises important questions regarding patient preference of, and access 
to, herbal cannabis and pharmaceutical alternatives.
The use of cannabinoids as therapeutic agents has generated a sig-
nificant amount of controversy. A detailed review of studies regarding 
prescribed oral medicinal cannabinoids has suggested that there is an 
increased risk of nonserious adverse events, but that the risks of long-
term exposure have not been characterized (10). There is a growing 
body of scientific literature highlighting serious adverse consequences 
associated with recreational cannabis use including psychiatric illness 
(eg, psychosis, depression) (11,12); impaired school (13), work (14) and 
driving performance (15); increased sexual risk taking and sexually 
transmitted infections (16); respiratory disease (17); cancer (18); myo-
cardial infarction (19); and immune impairment (20). The therapeutic 
benefit of cannabinoid therapy has largely been confined to the symp-
tomatic relief of nausea, anorexia and pain (21). 
Few studies have explored cannabis use among individuals in 
Canada living with HIV/AIDS (8,9,22,23). These studies have sug-
gested that cannabis use is approximately two- to threefold more 
prevalent among individuals living with HIV/AIDS compared with 
the general population. The principal indications for medicinal mari-
juana identified in these studies have included anorexia, nausea, pain 
and stress. Perceived and actual adverse consequences of cannabis in 
this population have not been thoroughly explored. 
The aims of the present exploratory study were to measure the 
prevalence of self-reported recreational and medicinal cannabis use, 
perceived benefits and adverse consequences associated with cannabis 
use, as well as to assess the predictors of cannabis use among HIV 
patients in Maritime Canada. Such research does not exist for the 
region. Providing care for individuals living with HIV in Maritime 
Canada can be a challenge due to the sociodemographic characteris-
tics of the region such as its highly rural nature, long commutes for 
health services for many patients, few resources, high poverty rates and 
stigma/discrimination associated with HIV infection. Maritime 
Canada represents a unique Canadian population, making such 
research critically important. The current study measured several 
psychological variables (eg, hopelessness, depression, self-efficacy) as 
well as high-risk behaviours and additional drug use to assess a wide 
range of novel predictors of cannabis use among this patient popula-
tion. A cross-sectional survey was performed in the two largest clinics 
serving individuals with HIV infection in this region. 
MEtHoDS
Definition of medicinal cannabis
The Canadian Senate Report on Cannabis Use notes that medicinal 
cannabis is used to achieve a therapeutic impact on a specified medical 
problem, and Health Canada, through their Marijuana Medical 
Access Regulations, outlines specific conditions for which medicinal 
cannabis use could be appropriate (6). For the current study, medicinal 
cannabis use was broadly defined as participants’ self-reported use of 
cannabis for medicinal purposes. The overlap between recreational 
and medicinal consumption makes it difficult to differentiate between 
these types of use. Nevertheless, such distinctions are important and, 
thus, were pursued in the current study. 
Study design
Data were collected at two Maritime hospital immunodeficiency clin-
ics. Site 1 recruited 80 participants and site 2 recruited 151 partici-
pants. Five participants were subsequently removed from data analysis 
because they did not indicate whether they used cannabis (n=226). 
Data collection procedures were consistent between sites. A clinic 
staff member approached potential participants with study informa-
tion during regular scheduled clinic visits. Individuals who expressed 
interest in the study met a member of the research team to further 
discuss the study and provide informed consent. Following informed 
consent, participants completed several questionnaires (see Measures 
section) while waiting to be seen by clinic staff. On completion, par-
ticipants sealed the questionnaires in an envelope. Participants’ CD4 
counts and viral load levels for the preceding year were sealed in the 
same envelope. Forms contained no personal identification.
All patients attending the hospital clinics over a six-month period 
who met inclusion criteria were invited to participate. Inclusion cri-
teria included: living with HIV or AIDS; being a patient at one of the 
HIV clinics in the study; and being ≥19 years of age. Exclusion criteria 
included: being an inmate at a correctional facility; and not being able 
to read English. Ethics approval was obtained from South East 
Regional Health Authority, New Brunswick; Capital District Health 
Authority, Nova Scotia; and Memorial University, St John’s, 
Newfoundland and Labrador.
Data analysis
Measures of central tendency, dispersion, frequency counts and pro-
portions were used to describe study variables. χ2 and independent-
samples t tests were used to assess univariate relationships between 
potential predictor variables and cannabis use. Binary logistic regres-
sion was subsequently used to examine the impact of preidentified 
significant predictor variables (through univariate analyses) in the 
prediction of cannabis use. 
Measures
General HIV questionnaire: This measure assessed demographic 
variables (eg, age, length of time living with HIV or AIDS, education 
level) as well as cannabis use, medication adherence, high-risk 
behaviour(s) and symptoms associated with HIV/AIDS.
The questionnaire collected information on the following variables: 
cannabis use (eg, Do you use medicinal marijuana?, Do you use marijuana 
other than medicinal marijuana?); frequency and quantity of cannabis use 
(eg, financial cost and weight used over specific time periods); reasons for 
cannabis use and level of effectiveness of cannabis for identified purposes 
of use; negative consequences of cannabis use; HIV medication adher-
ence; nature, frequency and severity of high-risk behaviour(s); reasons for 
high-risk behaviour(s); other drug, alcohol or tobacco use; nature and 
frequency of symptoms associated with HIV/AIDS; and the degree to 
which HIV/AIDS had impacted the participant. Most variables were 
measured through nominal data (eg, lists of reasons or symptoms that 
could be checked) or ordinal data (eg, rank order from high to low or low 
to high such as symptom severity questions), with some measuring ratio 
data (eg, weight/cost questions for cannabis use). 
The general HIV questionnaire was developed by members of the 
research team and health care professionals with expertise in HIV (eg, HIV 
physician, HIV nurse). The final measure was piloted for clarity and read-
ability using a small group of individuals who were not living with HIV. 
Self-efficacy: A brief self-report inventory measuring general self-
efficacy was used. It contained 10 items with a Likert scale ranging 
from 0 (“not at all true”) to 4 (“exactly true”). It has been used in 
>1000 research studies and exhibits satisfactory reliability and validity 
(24). Reliability was assessed in the current study using Cronbach’s α 
and was determined to be high at both research sites (α=0.93; 0.92).
Beck Hopelessness Scale: The Beck Hopelessness Scale (BHS) (25) is a 
widely used instrument for assessing negative expectations for the future. 
The scale has been used to detect hopelessness and pessimism among vari-
ous populations. The BHS has 20 true and false statements regarding 
negative expectations about the future. Scores can range from 0 to 20. 
There is also a symptom severity index: 0 to 3 = asymptomatic, 4 to 8 = 
mild, 9 to 14 = moderate, and >14 = severe. The test has been demon-
strated to exhibit high validity and reliability (25). Inter-rater reliability 
for the BHS has also been demonstrated to be high (r=0.93) (25).
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Brief Symptom Inventory 18: This is a brief self-report inventory 
designed to assess psychological distress and potential psychiatric disorders 
in medical and community populations (26). The Brief Symptom 
Inventory 18 was used in the current study to assess somatization, depres-
sion and anxiety. There are 18 questions, each containing a Likert scale 
ranging from 0 to 4, where 0 = “not at all” and 4 = “extremely”. The Brief 
Symptom Inventory 18 has been used with an HIV population in previous 
research and has satisfactory internal consistency (0.79 to 0.84) as well as 
convergent validity with similar measures (0.93 to 0.96) (26). In the cur-
rent study, reliabilities were as follows: somatization (α=0.99; 0.86), 
depression (α=1.0; 0.91) and anxiety (α=0.99; 0.84). 
rESuLtS
Demographic and psychological variables (table 1)
A total of 256 patients were invited to enroll in the study and 
231 (90%) agreed to participate. Five participants were removed from 
the analyses because they did not indicate cannabis or noncannabis 
use, resulting in a sample size of 226. The mean (± SD) age of partici-
pants was 45.8±9.0 years. Participants reported living with HIV for an 
average of 11.9±6.7 years. Overall, symptom severity was mild, with 
79.2% (179 of 226) of the sample reporting mild to no negative 
impacts from HIV. The participants’ sex was predominately male 
(202 of 226 [89.4%]), with 22 females and one transgender partici-
pant. Having a college/university education was reported by 59.3% 
(134 of 226) of the total sample and an additional 24.8% (56 of 226) 
reported completing high school. The majority of study participants 
resided in urban centres (139 of 226 [61.5%]). Cannabis use was sig-
nificantly associated with lower income level and rural residence by 
univariate analysis. 
Cannabis use
Current use of cannabis was reported by 38.5% (87 of 226) of study 
participants. When asked specifically whether medicinal cannabis was 
used, 21.8% (19 of 87) of the total cannabis-using sample reported 
medicinal use. Only 2.3% (two of 87) of the cannabis using participants 
Table 1
Selected demographic and psychological variables
Characteristic
Cannabis users  
(n=87)
Noncannabis users  
(n=139)
Total sample  
(n=226) Statistical analysis
Age, years, mean ± SD 45.9±9.1 45.7±9.0 45.8±9.0 P=0.913
Male sex 80 (92) 122 (87.8) 202 (89.4) χ2=2.40; P=0.121
Personal income, per year χ2=11.13; P=0.011
   <$20,000 29 (33.3) 31 (22.3) 60 (26.5)
   $20,000 to $29,999 14 (16.1) 23 (16.5) 37 (16.4)
   $30,000 to $49,999 27 (31) 37 (26.6) 64 (28.3)
   ≥$50,000 6 (6.9) 32 (23) 38 (16.8)
Sexuality χ2=3.09; P=0.214
   Gay, homosexual or queer 54 (61.9) 78 (56.1) 132 (58.3)
   Bisexual 3 (3.4) 8 (5.8) 11 (4.8)
   Heterosexual 16 (18.4) 40 (28.8) 56 (24.8)
Ethnicity χ2=1.19; P=0.276
   Caucasian 62 (71) 108 (77.7) 170 (75.2)
Employment χ2=0.17; P=0.681
   Employed 55 (63.2) 97 (69.8) 152 (67.3)
Education χ2=2.74; P=0.254
   Postsecondary education 45 (51.7) 89 (64) 134 (59.3)
   High-school graduate 24 (27.6) 32 (23) 56 (24.8)
   Below high-school graduate 15 (17.2) 17 (12.2) 32 (14.2)
Years diagnosed, mean ± SD 12.9±6.7 11.3±6.6 11.9±6.7 P=0.088
Urban 45 (51.7) 94 (67.6) 139 (61.5) χ2=3.99; P=0.046
Severity of symptoms χ2=3.04; P=0.219
   No negative symptoms 36 (41.4) 74 (53.2) 110 (48.7)
   Mild symptoms 25 (28.8) 44 (31.7) 69 (30.5)
   Moderate symptoms 15 (17.2) 15 (10.8) 30 (13.3)
Viral load at past three clinic visits, copies/mL,  
   mean ± SD
32,942±122,482 37,495±167,233 35,815±151,926 P=0.844
CD4 count at past three clinic visits, cells/μL,  
   mean ± SD
470±246 503±295 490±277 P=0.434
Counselling
   Individual 45 (51.7) 75 (54) 120 (53.1) χ2=0.022; P=0.88
   Group 14 (16.1) 16 (11.5) 30 (13.3) χ2=1.12; P=0.290
   Addictions 12 (13.8) 9 (6.5) 21 (9.3) χ2=3.63; P=0.057
   Peer support 20 (23) 25 (18) 45 (19.9) χ2=1.01; P=0.315
Self-efficacy, mean ± SD 33.06±5.30 32.48±5.44 32.70±5.38 P=0.435
Somatization, mean ± SD 9.18±5.06 8.20±5.76 8.58±5.51 P=0.200
Depression, mean ± SD 9.88±6.08 9.57±6.87 9.69±6.57 P=0.729
Anxiety, mean ± SD 8.80±5.06 8.51±5.65 8.62±5.42 P=0.697
Hopelessness, mean ± SD 3.63±4.38 4.58±5.18 4.22±4.90 P=0.153
Data presented as n (%) unless otherwise indicated. Not all participants provided data for each variable category; percentages and frequencies represent participant-
reported data based on subgroups and overall sample size
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reported exclusively using medicinal cannabis. However, when partici-
pants’ reasons for cannabis use were explored, only 8.1% (seven of 87) 
of the cannabis-using participants omitted medically related symptoms 
as reasons for use and instead chose ‘pleasure’ or ‘partying’ categories as 
reasons for use. Ten of the cannabis-using participants left the ‘reasons 
for use’ questions blank. Thus, 80.5% (70 of 87) of the cannabis-using 
participants reported a symptom-relieving benefit (eg, stress, anxiety, 
depression, anorexia). Nearly the entire cannabis-using sample (85 of 87 
[97.7%]) also reported recreational cannabis use. 
Participants reported using an average of 18.3±21.1 g (n=70) of 
cannabis in a typical month (median 14.5 g; quartiles 4.0 g, 25 g). Four 
participants reported consuming ≥60 g of cannabis in a typical month. 
With these four participants removed from the analysis, the average 
amount of cannabis consumed by participants in a typical month was 
14.4±12.3 g (n=66). Participants spent an average of $105.15±109.87 
on cannabis in a typical month (median $60.00, mode $0.00, range $0 
to $425.00; n=81). Participants had used cannabis for an average of 
22.4±10.7 years (n=83), making the average age of use initiation 
23.3±9.5 years (n=82). Forty participants reported no change in their 
cannabis use following diagnosis of HIV, whereas 21 participants 
reported reduced use following diagnosis and 17 participants reported 
increased use following diagnosis.
reasons for cannabis use 
Consumption for pleasure (ie, euphoriant effect) was the most com-
mon reason identified for cannabis use (Table 2). Other reasons 
included relief of anxiety, stress, physical pain, depression, nausea and 
appetite stimulation. Participants’ self-reported effectiveness of can-
nabis tended to fall in the ‘somewhat helpful’ to ‘very helpful’ range for 
relief of anxiety, stress, physical pain, depression, nausea, appetite 
stimulation, and facilitation of pleasure and partying. 
Consequences of cannabis use 
Some participants also noted negative consequences with cannabis use 
(Figure 1). Pertinent negative consequences included problems at 
work, financial stress, health issues, relationship problems and para-
noia. Three participants were of the opinion that their cannabis use 
interfered with adherence to antiretroviral medication. 
High-risk activity
Overall, 34.5% (n=78) of participants reported engaging in at least one 
type of high-risk activity, ranging from unsafe sexual practices to 
unhealthy eating (Table 3). The range of personal and/or societal 
impacts of these high-risk activities would certainly vary. Nonetheless, 
participants themselves labelled all of these behaviours/activities as 
‘high-risk’. The most prevalent reported high-risk activity was cogni-
tively orientated (ie, suicidal thoughts), with fewer participants reporting 
a translation into suicidal behaviour. Unsafe sexual practices and driving 
under the influence were the most commonly cited categories with dir-
ect risk for both participants and society at large. Participants noted 
several reasons for high-risk activity (Figure 2). ‘Other drug use’ and ‘not 
caring about the consequences’ were the most commonly cited reasons 
reported by participants for their engagement in high-risk activity. 
Cannabis use was noted as a reason for engaging in high-risk activities 
by 14.1% (11 of 78) of the high-risk activity group. 
There was a significant difference noted between the cannabis-
using and non-cannabis-using groups for the ‘driving under the influ-
ence of a substance’ category, with the cannabis-using group reporting 
higher levels of this activity (χ2=5.33; P=0.021). When individual 
types of ‘other drug use’ were explored, the cannabis-using group was 
more likely to report using ecstasy (χ2=5.71; P=0.017) and tobacco 
(χ2=15.32; P=0.001). 
Table 2
Number of participants reporting reasons for cannabis use 
and reported effectiveness for each reported reason for 
use













Anxiety (n=41) 1 1 1 14 21
Stress (n=51) 1 1 1 15 28
Physical pain (n=32) 0 0 1 12 16
Depression (n=33) 0 1 2 12 12
Appetite stimulation 
(n=46)
0 0 0 4 37
Nausea (n=28) 0 0 0 6 18
Pleasure (n=61) 1 1 4 26 21
Party (n=32) 1 0 3 12 13
Tremor (n=6) 1 0 1 2 2
Weakness (n=8) 1 1 0 2 4
Tiredness (n=12) 0 1 1 4 4
Vision problems (n=3) 0 1 0 2 0
Slurred speech (n=0) 0 0 0 0 0
Memory loss (n=1) 1 0 0 0 0
Constipation (n=2) 0 0 0 0 2
Headaches (n=18) 1 0 0 6 7
Diarrhea (n=6) 1 0 2 1 3
Tingling/numbness (n=14) 0 0 1 6 6
*n = number of participants reporting marijuana use for each reason for use; 
†Not all participants provided data on ‘Reported effectiveness’; therefore, 
reported effectiveness frequency counts do not equal n size for corresponding 
reason for cannabis use
Figure 1) Reported negative consequences due to cannabis use (n=87)
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Demographic characteristics, high-risk activity and substance use 
associated with cannabis use
The predictive power of significant variables identified through univari-
ate analyses were explored using a logistic regression model with can-
nabis use as the criterion variable. The overall model was significant 
(χ2=31.37 [7], P<0.001, R²=0.20) with an overall classification accuracy 
rate of 69.9%. For the predictor variables, lower income (χ2=7.98; 
P=0.046), ecstasy use (χ2=5.47; P=0.019) and smoking tobacco 
(χ2=7.43; P=0.006) were significant predictors of cannabis use (Table 4). 
Income was entered into the model as a categorical variable. 
DISCuSSIon
Previous Canadian research has suggested that cannabis use is com-
mon among HIV-positive cohorts in Central and Western Canada 
(9,23). The current study found that 38.5% of participants were cur-
rent users of cannabis. This prevalence of cannabis use is similar to 
HIV populations in other Canadian regions (23) and is at least 
3.5-fold higher than in the general population 35 to 55 years of age 
(4). There was a large range of reported cannabis consumption among 
participants in the present study. A recent study by Belle-Isle and 
Hathaway (8) also noted a wide range in the amount of cannabis con-
sumed, with an average consumption of 66 g of cannabis per month 
compared with 18.3 g per month in the present study. Participants in 
the Belle-Isle and Hathaway (8) study were predominately white 
males, had been living with HIV for an average of 10 years, and mainly 
resided in Ontario, British Columbia and Quebec. Both the Belle-Isle 
and Hathaway (8) study and the current study have also documented 
that cannabis use in HIV-infected cohorts is associated with signifi-
cant financial expenditure. Despite the significant cost of cannabis, 
current users had lower income levels than nonusers. Furler et al (9) 
had previously reported that lower socioeconomic level was associated 
with medicinal marijuana use in an Ontario HIV-positive cohort. 
Recreational cannabis consumption in early adolescence has also been 
associated with lower socioeconomic level (27). Our results are typical 
of other studies performed outside of Canada in terms of use quantity 
and monthly cost (28). 
Although the route of cannabis attainment was not explored in our 
questionnaire, previous research in Canadian HIV-positive cohorts have 
shown that cannabis is usually obtained from illegal sources (8,9). Some 
participants in the current study reported spending very little money on 
cannabis, raising important future research questions surrounding routes 
of attainment (eg, through friends/family, personal growing through a 
license to produce) and potential barriers to legal access. 
A higher prevalence of cannabis use by rural versus urban residents 
was observed. Previous research in Canada has documented high rates of 
cannabis use among young males residing in rural environments (29). 
This was not a predictor of cannabis use according to the regression analy-
sis, in which income level was retained as a significant association.
Most study participants reported a long history of cannabis use, 
often preceding the HIV diagnosis itself, highlighting cannabis use as 
a long-term behaviour. The level of cannabis consumption did not 
change significantly for many study participants following the diagno-
sis of HIV infection.
Formulating an objective definition of ‘medicinal cannabis’ poses a 
significant precisional challenge, given that large cross-sectional stud-
ies indicate that it is consumed principally for its mood-altering prop-
erties rather than for relief of medical symptoms. Recreational use was 
common in our current study sample, in which cannabis use appears to 
have been a long-standing practice. We defined medicinal cannabis 
according to the study participants’ opinions, recognizing that such a 
definition would be highly subjective. The use of prescribed cannabis 
subsequent to the diagnosis of HIV infection would be a more precise 
definition of medicinal cannabis use, but route of cannabis ascertain-
ment was not explored in the present study. According to our defin-
ition, 21.8% (19 of 87) of participants reported using medicinal 
cannabis. Almost the entire population used cannabis for recreational 
Table 3
Self-reported high-risk activity and other substance use
Cannabis users 
(n=87)
Non-cannabis users  
(n=139)
Total sample  
(n=226) Statistical analysis
Unsafe drug use (eg, sharing needles) 5 (5.7) 6 (4.3) 11 (4.9) χ2=0.24; P=0.627
Suicidal behaviour 2 (2.3) 7 (5) 9 (4) χ2=0.46; P=0.500
Suicidal thoughts 12 (13.8) 22 (15.8) 34 (15) χ2=0.173; P=0.677
Driving under the influence of a substance 11 (12.6) 6 (4.3) 17 (7.5) χ2=5.33; P=0.021
Unsafe sexual practices 14 (16.1) 18 (12.9) 32 (14.2) χ2=0.41; P=0.524
HIV medication nonadherence 8 (9.2) 16 (11.5) 24 (10.6) χ2=0.30; P=0.582
Fighting 4 (4.6) 6 (4.3) 10 (4.4) χ2=0.00; P=1.000
Cocaine use 6 (6.9) 8 (5.8) 14 (6.2) χ2=0.14; P=0.712
Acid use 3 (3.4) 0 (0) 3 (1.3) χ2=2.62; P=0.105
Ecstasy use 9 (10.3) 3 (2.2) 12 (5.3) χ2=5.71; P=0.017
Alcohol use 41 (47.1) 49 (35.3) 90 (39.8) χ2=3.42; P=0.065
Tobacco use (smoking) 50 (57.5) 44 (31.7) 94 (41.6) χ2=15.32; P=0.001
Number of cigarettes per day, mean ± SD 13.9±9.7 9.1±11.7 11.0±11.2 P=0.012
Data presented as n (%) unless otherwise indicated
Table 4
Variables in the regression equation
Predictors b Se Wald df P exp(b) 95% CI
Geographical (rural versus urban) 0.44 0.34 1.72 1 0.190 1.56 0.80–3.01
Income, per year 7.98 3 0.046
   >$50,000 1.55 0.57 7.40 1 0.007 4.71 1.54–14.40
   $30,000 to $49,999 0.15 0.39 0.15 1 0.700 1.16 0.54–2.50
   $20,000 to $29,999 0.41 0.46 0.79 1 0.375 1.50 0.61–3.67
Smoking cigarettes −0.88 0.32 7.43 1 0.006 0.41 0.22–0.78
Ecstasy use −1.72 0.73 5.47 1 0.019 0.18 0.04–0.76
Driving under the influence of a substance −0.68 0.58 1.39 1 0.239 0.51 0.16–1.57
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purposes, while a large proportion (80.5%; 70 of 87) acknowledged 
some symptom benefit. 
Thus, 8.4% (19 of 226) of our study sample were using cannabis 
that they defined as medicinal cannabis, although only two partici-
pants reported using it exclusively for medicinal purposes. This is simi-
lar to a large British Columbia survey of HIV-positive individuals, 
which found that 14% were current users of medicinal marijuana (22). 
These statistics highlight the intrinsic ambiguity of defining medicinal 
cannabis in this population, in which a large proportion of users use 
cannabis for recreational purposes, with the additional acknowledg-
ment of medicinal benefits. This ambiguity could pose a significant 
barrier for prescribers. Recreational use may be a partial explanation 
for why most cannabis in the HIV-positive population, as in the 
Canadian population at large, is obtained from illegal sources (8,9). 
This being said, more research is needed to understand local and sys-
temic barriers to legal access. 
The self-reported medicinal benefits of cannabis use among study 
participants were consistent with published research (8,9,22,23,30,31). 
The most commonly reported reasons for use included stimulation of 
appetite, relief of anxiety and stress, and alleviation of pain. The only 
approved synthetic cannabinoid in Canada for HIV/AIDS is dron-
abinol, indicated for anorexia associated with weight loss. Four clinical 
trials assessing its use for anorexia in HIV/AIDS have been published 
(32-35). Some of these trials have documented an orexigenic benefit, 
but there is currently insufficient evidence to document an impact on 
weight. Dronabinol was compared with smoked marijuana in one trial, 
with no evidence of therapeutic advantage (33). 
Numerous studies have documented high rates of emotional dis-
tress and depression in HIV-positive patients undergoing treatment 
(36,37). Although our participants reported improvement in stress 
and anxiety with cannabis, there is always the risk that such effects 
may be short-term in nature, given cannabis’s euphoriant effect. As 
well, given the growing evidence for an association between cannabis 
and depression, anxiety, psychosis and amotivational state (11,19,38), 
any such benefits derived from cannabis use need to be weighed 
against potential risks. Further controlled research is needed to assess 
any potential benefits or harms of cannabis use for such cognitive-
affective conditions, especially given the high degree of self-reported 
benefit among participants in the current study. 
A large proportion of cannabis users in our study reported the 
alleviation of pain as a benefit. One randomized, crossover trial com-
paring smoked cannabis to placebo for neuropathic pain in HIV docu-
mented greater pain relief in the treatment arm (39). 
Negative consequences of cannabis use were less commonly reported 
compared with self-reported benefits of cannabis use. The more com-
mon reported consequences included “financial stress” and “feeling 
paranoid”. Paranoia was a noted consequence of cannabis use by 26% of 
HIV-positive participants in a study by Ware et al (23), which is similar 
to the findings in the current study. Work-related problems were 
reported by 8.1% (seven of 87) of cannabis users. Research has high-
lighted that heavy cannabis use can have negative implications on cog-
nitive functioning, which could adversely impact individuals in certain 
work situations (14,40). Cannabis may adversely affect several functions 
involved in operation of machinery and motor vehicles (eg, balance, 
coordination, concentration, short-term memory) (41). 
There is a paucity of research exploring cannabis use and its poten-
tial associations with high-risk behaviour among HIV populations. We 
identified significant relationships between cannabis use and other 
high-risk activities (driving under the influence of a substance and use 
of ecstasy and tobacco). We found no other studies reporting a rela-
tionship between cannabis use and driving under the influence among 
persons living with HIV/AIDS. Acute cannabis consumption is 
strongly associated with risk of motor vehicle collision and fatality 
(15,42). This excess risk is dose related and amplified by the use of 
alcohol or other substances (12,43), and could be a potential contribu-
tor to the rising proportion of accidental/violent non-AIDS-related 
deaths in the post-highly active antiretroviral therapy era (44). 
Cannabis use was also associated with an increased use of other 
substances (eg, ecstasy), a finding noted in other research (45,46). 
Tobacco and ecstasy use were two variables shown to be significant 
predictors through regression modelling. This lends support to canna-
bis prevention and treatment approaches that encompass additional 
substances. Smoking cessation programs are now widely advocated in 
the HIV-infected population, who have a significant increased cardio-
vascular morbidity (47,48). The high concurrence of both tobacco and 
cannabis use in this population could potentially aggravate shared 
morbidities (chronic bronchitis, lung cancer, coronary disease) and 
diminish the success of tobacco cessation programs.
Study limitations
The current study obtained a high response rate (90%) and included a 
relatively large sample size compared with previous surveys of cannabis 
use in the HIV-positive population. This was a predominantly 
Caucasian cohort with very few female study participants; therefore, 
findings may not be generalizable to women and non-Caucasian indi-
viduals infected with HIV. Future research involving larger samples 
would provide enhanced statistical power and would permit a better 
assessment of the subgroup using cannabis from legal sources, which 
were not explicitly studied. Although our survey findings are consist-
ent with other Canadian research on HIV infection and cannabis use, 
the potential for participant recall bias and subjective response using 
this methodology is significant. 
ConCLuSIonS
Cannabis use is prevalent among individuals living with HIV/AIDS in 
Maritime Canada, and is similar to other Canadian geographical regions. 
Despite describing symptom-related benefits from cannabis use, only a 
small proportion of patients in the present study self-identified as medi-
cinal cannabis users. Cannabis use was characterized as a long-standing 
recreational behaviour, which preceded the diagnosis of HIV infection in 
most cases. These findings highlight the challenges surrounding both the 
definition and prescription of medicinal cannabis in the HIV population. 
While participants self-reported medicinal symptom relief from cannabis 
use, an association with high-risk behaviour (other substance use) was 
demonstrated. Adverse psychological outcomes were not identified on 
psychometric testing. Although Canada has more forms of prescribed or 
authorized medicinal cannabis than any other nation, overall prescription 
remains low. This paradox is not reflective of inadequate supply and 
deserves further research. Questions surrounding barriers to legal access 
need to be examined in this context.
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